Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SRx Health Solutions (SRXH) Current Deferred Revenue (2019 - 2025)

SRx Health Solutions' Current Deferred Revenue history spans 6 years, with the latest figure at $38000.0 for Q2 2025.

  • For Q2 2025, Current Deferred Revenue changed N/A year-over-year to $38000.0; the TTM value through Jun 2025 reached $38000.0, changed N/A, while the annual FY2024 figure was $500000.0, 7042.86% up from the prior year.
  • Current Deferred Revenue reached $38000.0 in Q2 2025 per SRXH's latest filing, down from $500000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $500000.0 in Q4 2024 to a low of $7000.0 in Q4 2023.
  • Average Current Deferred Revenue over 4 years is $229000.0, with a median of $169000.0 recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: fell 9.09% in 2021, then surged 7042.86% in 2024.
  • A 4-year view of Current Deferred Revenue shows it stood at $300000.0 in 2021, then crashed by 97.67% to $7000.0 in 2023, then soared by 7042.86% to $500000.0 in 2024, then tumbled by 92.4% to $38000.0 in 2025.
  • Per Business Quant, the three most recent readings for SRXH's Current Deferred Revenue are $38000.0 (Q2 2025), $500000.0 (Q1 2025), and $500000.0 (Q4 2024).